Statin-induced vulnerable plaque regression after atorvastatin treatment: serial evaluation by 18F-fluorodeoxyglucose positron emission tomography study.

Trial Profile

Statin-induced vulnerable plaque regression after atorvastatin treatment: serial evaluation by 18F-fluorodeoxyglucose positron emission tomography study.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jul 2009

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atherosclerosis; Hyperlipidaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Jan 2009 Status changed from not yet recruiting to completed.
    • 08 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Jan 2009 Actual start date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top